Cargando…
Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model
BACKGROUND: Anticancer compound 3-bromopyruvate (3-BrPA) suppresses cancer cell growth via targeting glycolytic and mitochondrial metabolism. The malignant peripheral nerve sheath tumor (MPNST), a very aggressive, therapy resistant, and Neurofibromatosis type 1 associated neoplasia, shows a high met...
Autores principales: | Linke, Christian, Wösle, Markus, Harder, Anja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501688/ https://www.ncbi.nlm.nih.gov/pubmed/32948135 http://dx.doi.org/10.1186/s12885-020-07397-w |
Ejemplares similares
-
Screening the yeast genome for energetic metabolism pathways involved in a phenotypic response to the anti-cancer agent 3-bromopyruvate
por: Lis, Paweł, et al.
Publicado: (2016) -
MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro
por: Fischer-Huchzermeyer, Susan, et al.
Publicado: (2017) -
Synergistic Effect of 3-Bromopyruvate in Combination with Rapamycin Impacted Neuroblastoma Metabolism by Inhibiting Autophagy
por: Gan, Lei, et al.
Publicado: (2020) -
In vitro and in vivo effects of 3-bromopyruvate against Echinococcus metacestodes
por: Xin, Qi, et al.
Publicado: (2019) -
BCRP expression in schwannoma, plexiform neurofibroma and MPNST
por: de Vries, Maurits, et al.
Publicado: (2017)